Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
LAZCLUZE: selected primary-label renal guidance and limits
Product / population
Adult oral LAZCLUZE with amivantamab in the labeled lung-cancer regimen; partner-drug guidance is separate.
Renal method
eGFR 30-89 mL/min as printed; supporting PK uses CKD-EPI
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
LAZCLUZE: source applicability and renal evidence limits
eGFR <30, including ESRD: not studied. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Review amivantamab and the complete regimen independently.
DailyMed / product prescribing information · Adult oral LAZCLUZE with amivantamab in the labeled lung-cancer regimen; partner-drug guidance is separate.
Renal method: eGFR 30-89 mL/min as printed; supporting PK uses CKD-EPI Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
eGFR <30, including ESRD: not studied.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Sections 8.6 and 12.3
No renal adjustment is recommended at eGFR 30-89 mL/min. Severe impairment or ESRD below 30 has not been studied. No dialysis schedule is established. This statement concerns lazertinib and does not replace partner-drug, prophylaxis or regimen-specific toxicity instructions.
RDM72-lazertinib-lazcluze-label-1 · Source locator: Sections 8.6 and 12.3
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
